Price
$80.05+8.99%Social Signal Score
Analyst Ratings
13 analystsRevenue
$214.06M+142.30%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher J. Reading
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 6,374
- Beta
- 1.13
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.68
Financials
Revenue
$214.06M+142.3%Net Income
$1.60M-66.6%EBITDA
$27.89M+97.4%Free Cash Flow
$28.81M+343.5%EPS (diluted)
$0.25-34.2%Shares Outstanding (diluted)
15.07M+20.4%Operating Expenses
$0.00Cash & Debt
$24.89MReturn of Capital
$33.10MRevenue by Segment (annual)
$780.99MDividend per Share
$0.46Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $780.99M | $15.06M | $1.42 |
| 2024 | $671.35M | $26.46M | $1.84 |
| 2023 | $604.80M | $14.67M | $1.28 |
| 2022 | $553.14M | $28.27M | $3.34 |
| 2021 | $495.02M | $27.82M | $4.49 |
| 2020 | $422.97M | $30.56M | $4.09 |
| 2019 | $481.97M | $28.15M | $4.49 |
| 2018 | $453.91M | $10.10M | $0.80 |
| 2017 | $414.05M | $22.26M | $1.76 |
| 2016 | $356.55M | $20.55M | $1.64 |
| 2015 | $331.30M | $22.28M | $1.77 |
| 2014 | $305.07M | $19.77M | $1.62 |
| 2013 | $264.06M | $12.72M | $1.05 |
| 2012 | $252.09M | $17.93M | $1.52 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from USPH's reported EPS growth of -0.5% a year over 13 years.
- EPS in 5 years
- $0.97
- Implied price
- $53.24
- Return from $83.72
- -8.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $26.47 — -68.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 39 | 47 | 55 | 63 | 71 |
|---|---|---|---|---|---|
| -10.5% | -23.3% | -20.4% | -17.8% | -15.6% | -13.5% |
| -5.5% | -19.0% | -15.9% | -13.2% | -10.9% | -8.7% |
| -0.5% | -14.7% | -11.5% | -8.7% | -6.1% | -3.9% |
| 4.5% | -10.4% | -7.0% | -4.1% | -1.4% | 1.0% |
| 9.5% | -6.2% | -2.6% | 0.5% | 3.3% | 5.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (5)
- Newsbusinesswire.com·15d ago·Neutral
U.S. Physical Therapy Announces the Appointment of New Board Member Myra Davis HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced that its Board of Directors (the “Board”) approved the appointment of Ms. Myra Davis to serve as a member of the Board, effective October 1, 2026. Myra Davis currently serves as the Exe…
View source ↗ - Newsdefenseworld.net·38d ago·Neutral
U.S. Physical Therapy Bets on Hospital Alliances to Drive Visits, Reimbursement U.S. Physical Therapy (NYSE: USPH) is pursuing growth through clinic openings, acquisitions and a newer hospital-alliance strategy that Chief Executive Officer Chris Reading said could expand patient volumes and improve reimbursement. Speaking at an investor event, Reading said the company operates in 45 states with just under 800 locations focused primarily on orthopedic and musculoskeletal care,
View source ↗ - Newsmarketbeat.com·40d ago·Neutral
U.S. Physical Therapy Bets on Hospital Alliances to Drive Visits, Reimbursement U.S. Physical Therapy NYSE: USPH is pursuing growth through clinic openings, acquisitions and a newer hospital-alliance strategy that Chief Executive Officer Chris Reading said could expand patient volumes and improve reimbursement.
View source ↗ - Newsbusinesswire.com·53d ago·Neutral
U.S. Physical Therapy Announces CFO HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services (“IIP”), today announced that Nchacha Etta will serve as the Company's Executive Vice President and Chief Financial Officer, effective as of September 1, 2026. Jason Curtis, the Company's Senior Vice President, Finance and Accounting, served as …
View source ↗ - Newsmarketbeat.com·58d ago·Negative
U.S. Physical Therapy Q2 Earnings Call Highlights U.S. Physical Therapy NYSE: USPH reported second-quarter 2026 revenue growth supported by higher patient volumes, improved reimbursement rates and the early rollout of hospital-affiliation agreements, while elevated employee healthcare claims and upfront staffing costs pressured physical therapy margins.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.76 per share
Typical surprise -1.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.75 vs $0.81miss
- Wed, May 6$0.46 vs $0.55miss
- Wed, Feb 25$0.67 vs $0.67beat
- Wed, Nov 5$0.66 vs $0.67miss
- Wed, Aug 6$0.81 vs $0.71beat
- Wed, May 7$0.48 vs $0.46beat
Estimates and results for USPH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by USPH officers and directors.
- Bought
- $497k
- Sold
- $4.8m
6 trades
37 trades
- Minan Peter Francisbought
- Minan Peter Francisbought
- Minan Peter Francisbought
- Minan Peter Francisbought
- Reeve Graham D.sold
- Reeve Graham D.sold
- Reeve Graham D.sold
- Binstein Richardsold
57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Sep 7, 2026 (53d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2025 (20d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed May 14, 2025 (27d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Feb 12, 2025 (14d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 6, 2024 (20d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 3, 2024 (17d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jun 11, 2023 (18d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.